Evidence map›Paper›PMID 40442559›Full record

ArticleMolecular diversity2026

Discovery of novel purine analogues against breast cancer selectively targeting CDK2: optimization, synthesis, biological evaluation and docking study.

Mahesh Rupapara, Nishith Teraiya, Chetan Sangani, Khushal Kapadiya, Nishant Patel

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahesh RupaparaDepartment of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210008, People's Republic of China.
Nishith TeraiyaDepartment of Pharmaceutical Chemistry, K B Institute of Pharmaceutical Education and Research, Kadi Sarva Vishvavidhyalay, Gandhinagar, Gujarat, 382023, India.
Chetan SanganiDepartment of Chemistry, Gujarat University, Government Science College Sector-15, Gandhinagar, Gujarat, 382016, India.
Khushal KapadiyaBRCC Laboratory, Department of Chemistry, School of Science, RK University, Rajkot, Gujarat, 360 020, India. Khushal.kapadiya@rku.ac.in.
Nishant PatelDepartment of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210008, People's Republic of China. nishantpatel@njmu.edu.cn.

Funding

Jiangsu Postdoctoral Research Foundation 2022ZB799
6 · The paper itself

Abstract

CDK2 inhibition is a promising breast cancer treatment. Purines target CDK2 and are effective against breast cancer, proving a therapeutic scaffold. New purine-based compounds, 5a-5j were synthesized using chloro-amine coupling and phenacylation in a two-step procedure, characterized, and tested for anticancer activity. The highest yield (82%), without column purification or a costly catalyst like Pd/Cu, was achieved with concentrated HCl. The synthesis and site-selective substitution at the purine ring's C-2 position were confirmed by

Indexed as

Antineoplastic AgentsBreast NeoplasmsCyclin-Dependent Kinase 2Drug DiscoveryProtein Kinase InhibitorsPurinesAnimalsCell Line, TumorCell ProliferationChlorocebus aethiopsDrug Screening Assays, AntitumorFemaleHumansMolecular Docking SimulationStructure-Activity RelationshipVero CellsAntineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2Protein Kinase InhibitorspurinePurinesCDK2 inhibitionCytotoxicityDockingPurine nucleoside

Identifiers

PMID40442559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.